Adverse drug reactions

References 

1. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J. 2002;167:1269–1270
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520–1528
   • MEDLINE
   • CrossRef
3. Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
   • MEDLINE
   • CrossRef
4. Othersen JB, Maize JC, Woolson RF, et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179–3185
   • CrossRef
5. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–829
   • Abstract
   • Full Text
   • Full-Text PDF (75 KB)
   • CrossRef
6. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003;327:1222–1225
   • CrossRef
7. Dukes MNG, Aronson JK. Meyler’s side effects of drugs. 15th edn.. Amsterdam: Elsevier; 2006;
8. Breathnach SM, Hinter H. Adverse drug reactions and the skin. 1st edn.. Oxford: Blackwell Scientific Publications; 1992;
9. Butt TF, Evans B. Drug-induced headache. Adverse Drug React Bull. 2006;240:919–922
10. British National Formulary. Royal Pharmaceutical Society of Great Britain. London: British Medical Association. Available at: www.bnf.org